839 related articles for article (PubMed ID: 12107550)
21. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate.
Kobayashi K; Mimura N; Fujii H; Minami H; Sasaki Y; Shimada N; Chiba K
Clin Cancer Res; 2000 Aug; 6(8):3297-303. PubMed ID: 10955816
[TBL] [Abstract][Full Text] [Related]
22. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
24. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
25. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
26. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.
Rehmel JL; Eckstein JA; Farid NA; Heim JB; Kasper SC; Kurihara A; Wrighton SA; Ring BJ
Drug Metab Dispos; 2006 Apr; 34(4):600-7. PubMed ID: 16415119
[TBL] [Abstract][Full Text] [Related]
27. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Hidestrand M; Oscarson M; Salonen JS; Nyman L; Pelkonen O; Turpeinen M; Ingelman-Sundberg M
Drug Metab Dispos; 2001 Nov; 29(11):1480-4. PubMed ID: 11602525
[TBL] [Abstract][Full Text] [Related]
28. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Benetton SA; Fang C; Yang YO; Alok R; Year M; Lin CC; Yeh LT
Drug Metab Pharmacokinet; 2007 Apr; 22(2):78-87. PubMed ID: 17495414
[TBL] [Abstract][Full Text] [Related]
29. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
30. In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes.
Zhang Y; Guo X; Lin ET; Benet LZ
Pharmacology; 1999 Mar; 58(3):147-59. PubMed ID: 9925971
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome P450 2E1 is the primary enzyme responsible for low-dose carbon tetrachloride metabolism in human liver microsomes.
Zangar RC; Benson JM; Burnett VL; Springer DL
Chem Biol Interact; 2000 Mar; 125(3):233-43. PubMed ID: 10731522
[TBL] [Abstract][Full Text] [Related]
32. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
33. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide.
Zhang L; Fitzloff JF; Engel LC; Cook CS
Xenobiotica; 2001 Feb; 31(2):73-83. PubMed ID: 11407536
[TBL] [Abstract][Full Text] [Related]
34. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
35. Metabolism of a novel phosphodiesterase-IV inhibitor (V11294) by human hepatic cytochrome P450 forms.
Subrahmanyam V; Renwick AB; Walters DG; Price RJ; Tonelli AP; Lake BG
Xenobiotica; 2002 Jun; 32(6):521-34. PubMed ID: 12160484
[TBL] [Abstract][Full Text] [Related]
36. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
Feierman DE; Lasker JM
Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
[TBL] [Abstract][Full Text] [Related]
37. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
38. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
39. Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites.
Oda Y; Kharasch ED
J Pharmacol Exp Ther; 2001 Apr; 297(1):410-22. PubMed ID: 11259570
[TBL] [Abstract][Full Text] [Related]
40. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Taguchi K; Konishi T; Nishikawa H; Kitamura S
Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]